Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC70 | AZD8055 | 3 | 72 | 3.2 | 1558.3 | 2811.8 | 517.3 | 0.505 | 0.571 | 0.554 | 2.442 | HCC70 AZD8055 0 3 72 |
| Hs 578T | GDC-0980 | 3 | 72 | 0.32 | 1561.3 | 4064.8 | 571.3 | -0.495 | 0.426 | 0.384 | 2.831 | Hs578T GDC0980 3 |
| HCC70 | AZD8055 | 3 | 72 | 0.32 | 1565.0 | 2811.8 | 517.3 | -0.495 | 0.573 | 0.557 | 2.442 | HCC70 AZD8055 0 3 72 |
| HCC38 | Trametinib | 3 | 72 | 1.0 | 1567.3 | 3307.5 | 1180.5 | 0.0 | 0.210 | 0.474 | 1.486 | HCC38 Trametinib 0 3 72 |
| BT-20 | Sirolimus | 2 | 72 | 0.032 | 1569.0 | 3606.8 | 1018.6 | -1.49 | 0.267 | 0.435 | 1.824 | BT20 Rapamycin 0 2 |
| HCC38 | GDC-0980 | 1 | 72 | 3.2 | 1570.3 | 4439.8 | 1295.5 | 0.505 | 0.114 | 0.354 | 1.777 | HCC38 GDC0980 0 1 72 |
| HCC38 | Torin2 | 1 | 72 | 0.1 | 1570.5 | 4443.3 | 1295.5 | -1.0 | 0.114 | 0.353 | 1.778 | HCC38 Torin2 0 1 72 |
| HCC38 | PI103 | 2 | 72 | 1.0 | 1577.8 | 2947.5 | 690.5 | 0.0 | 0.484 | 0.535 | 2.094 | HCC38 PI103 0 2 72 |
| Hs 578T | AS605240 | 1 | 72 | 3.2 | 1577.8 | 3529.0 | 873.1 | 0.505 | 0.341 | 0.447 | 2.015 | Hs578T AS605240 1 |
| BT-20 | Sirolimus | 3 | 72 | 0.0032 | 1578.5 | 3288.5 | 586.9 | -2.49 | 0.489 | 0.480 | 2.486 | BT20 Rapamycin 0 3 |
| HCC38 | Dactolisib | 1 | 72 | 0.32 | 1580.5 | 4578.0 | 1295.5 | -0.495 | 0.115 | 0.345 | 1.821 | HCC38 BEZ235 0 1 72 |
| HCC70 | AZD-6482 | 2 | 72 | 0.1 | 1580.5 | 2468.8 | 722.8 | -1.0 | 0.555 | 0.640 | 1.772 | HCC70 AZD6482 0 2 72 |
| BT-549 | AZD8055 | 2 | 72 | 0.32 | 1583.8 | 4500.0 | 1249.6 | -0.495 | 0.137 | 0.352 | 1.848 | BT549 AZD8055 0 2 72 |
| HCC70 | AZD8055 | 3 | 72 | 1.0 | 1584.0 | 2811.8 | 517.3 | 0.0 | 0.581 | 0.563 | 2.442 | HCC70 AZD8055 0 3 72 |
| BT-20 | Alpelisib | 1 | 72 | 3.2 | 1584.5 | 6091.5 | 1443.3 | 0.505 | 0.046 | 0.260 | 2.077 | BT20 BYL719 0 1 |
| HCC70 | AS605240 | 2 | 72 | 3.2 | 1585.8 | 2466.3 | 722.8 | 0.505 | 0.558 | 0.643 | 1.771 | HCC70 AS605240 0 2 72 |
| HCC70 | AS605240 | 3 | 72 | 3.2 | 1585.8 | 2821.5 | 517.3 | 0.505 | 0.580 | 0.562 | 2.447 | HCC70 AS605240 0 3 72 |
| HCC70 | AZD8055 | 2 | 72 | 0.1 | 1587.3 | 2388.0 | 722.8 | -1.0 | 0.578 | 0.665 | 1.724 | HCC70 AZD8055 0 2 72 |
| Hs 578T | Pictilisib | 2 | 72 | 3.2 | 1587.5 | 3563.3 | 624.7 | 0.505 | 0.450 | 0.446 | 2.512 | Hs578T GDC0941 2 |
| BT-549 | Dactolisib | 2 | 72 | 0.1 | 1590.0 | 4628.8 | 1249.6 | -1.0 | 0.136 | 0.344 | 1.889 | BT549 BEZ235 0 2 72 |
| BT-20 | Everolimus | 2 | 72 | 1.0 | 1591.0 | 3213.5 | 1018.6 | 0.0 | 0.309 | 0.495 | 1.658 | BT20 Everolimus 0 2 |
| HCC70 | WYE-125132 | 3 | 72 | 3.2 | 1591.0 | 2762.5 | 517.3 | 0.505 | 0.592 | 0.576 | 2.417 | HCC70 WYE125132 0 3 72 |
| Hs 578T | Pictilisib | 1 | 72 | 3.2 | 1591.5 | 3610.0 | 873.1 | 0.505 | 0.341 | 0.441 | 2.048 | Hs578T GDC0941 1 |
| BT-549 | AZD8055 | 2 | 72 | 3.2 | 1591.7 | 4500.0 | 1249.6 | 0.505 | 0.140 | 0.354 | 1.848 | BT549 AZD8055 0 2 72 |
| BT-20 | Sirolimus | 3 | 72 | 0.1 | 1592.5 | 3288.5 | 586.9 | -1.0 | 0.494 | 0.484 | 2.486 | BT20 Rapamycin 0 3 |